Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience.
In Hodgkin's disease where the majority of patients are long-term survivors secondary myeloid malignancies are a well-documented complication. The survival of those who develop secondary myelodysplasia/acute myeloid leukaemia (MDS/AML) is historically said to be extremely poor. This study from the BNLI database of over 4900 patients with Hodgkin's disease reports long-term follow-up of 30 patients with secondary MDS/AML. Five patients have survived at least 5 yr (1>12 yr) from the time of diagnosis of AML. These patients were significantly younger (p=0.03) than those who succumbed to this complication and each also had standard or favourable risk cytogenetics. The actuarial 5- and 10-yr survival rates are 17.4% (7.7-34.9%, 95% CI) and 8.7% (1.9-31.7%, 95% CI), respectively. There is therefore a subgroup of patients who will achieve long-term survival despite the development of secondary myeloid malignancy.
Harrison
C N
CN
Department of Haematology, University College London Medical School, UK. c.harrison@ucl.ac.uk
Vaughan
G
G
Devereux
S
S
Linch
D C
DC
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000150:complications* / Q000628:therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007951:Leukemia, Myeloid / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology